111.56

0.21% -0.24

Pre-market: 102.00 -9.56 -8.57%

Ligand Pharmaceuticals Inc (LGND)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Ligand Pharmaceuticals Inc stock is traded at $111.56, with a volume of 131.94K. It is down -0.21% in the last 24 hours and up +4.86% over the past month. Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Previous Close:

$111.80

Open:

$111.59

24h Volume:

131.94K

Relative Volume:

1.24

Market Cap:

$2.10B

Revenue:

$118.31M

Net Income/Loss:

$96.34M

P/E Ratio:

77.47

EPS:

1.44

Net Cash Flow:

$-19.62M

1W Performance:

-8.62%

1M Performance:

+4.86%

6M Performance:

+28.78%

1Y Performance:

+91.95%

1-Day Range:

$109.53

$112.00

1-Week Range:

$109.44

$125.76

52-Week Range:

$57.00

$129.90

Ligand Pharmaceuticals Inc Stock (LGND) Company Profile

Name

Ligand Pharmaceuticals Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

858-550-7500

Address

3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA

Employee

Twitter

@Ligand_LGND

Next Earnings Date

2024-11-07

Latest SEC Filings

LGND's Discussions on Twitter

Compare LGND with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LGND	111.56	2.10B	118.31M	96.34M	-19.62M	1.44
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-21	Resumed	Stephens	Overweight
Feb-04-21	Reiterated	H.C. Wainwright	Buy
Oct-06-20	Initiated	Barclays	Overweight
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight
May-03-19	Reiterated	H.C. Wainwright	Buy
Mar-06-19	Reiterated	H.C. Wainwright	Buy
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy
Sep-11-18	Reiterated	Argus	Buy
Aug-17-18	Initiated	Goldman	Neutral
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy
Dec-27-17	Reiterated	H.C. Wainwright	Buy
Sep-05-17	Resumed	H.C. Wainwright	Buy
Oct-05-16	Reiterated	H.C. Wainwright	Buy
Aug-05-16	Downgrade	Deutsche Bank	Hold → Sell
Mar-11-16	Initiated	Sidoti	Buy
Mar-03-16	Initiated	H.C. Wainwright	Buy

View All

Ligand Pharmaceuticals Inc Stock (LGND) Latest News

04:11 AM

Royce & Associates LP Sells 4,996 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat

04:11 AM

Nov 16, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings - Yahoo Finance

Nov 16, 2024

Nov 14, 2024

Janus Henderson Group PLC Expands Stake in Ligand Pharmaceuticals Inc - GuruFocus.com

Nov 14, 2024

Ligand Pharmaceuticals to Present at Stifel 2024 Healthcare Conference | LGND Stock News - StockTitan

Nov 14, 2024

Nov 12, 2024

Royal Bank of Canada Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat

Nov 12, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Given New $150.00 Price Target at Barclays - Defense World

Nov 12, 2024

Ligand Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Canada

Nov 12, 2024

Nov 11, 2024

LGND: 3Q Sales Surprise to the Upside - Zacks Small Cap Research

Nov 11, 2024

Lisanti Capital Growth LLC Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat

Nov 11, 2024

Nov 09, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Benchmark Analyst Says - MarketBeat

Nov 09, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Shares Down 7.7%Should You Sell? - MarketBeat

Nov 09, 2024

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 09, 2024

Villere ST Denis J & Co. LLC Lowers Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat

Nov 09, 2024

Earnings call: Ligand reports robust Q3 growth, raises 2024 forecast - Investing.com India

Nov 09, 2024

Nov 08, 2024

Earnings call: Ligand reports robust Q3 growth, raises 2024 forecast By Investing.com - Investing.com Nigeria

Nov 08, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $150.00 at Barclays - MarketBeat

Nov 08, 2024

Oppenheimer Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat

Nov 08, 2024

A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals - Benzinga

Nov 08, 2024

Ligand Pharmaceuticals (NASDAQ:LGND) Given Buy Rating at HC Wainwright - MarketBeat

Nov 08, 2024

Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price - Yahoo Finance

Nov 08, 2024